Adding to PDUFA
Legislation to reauthorize the Prescription Drug User Fee Act (PDUFA) and several other new and old FDA user fee programs
may also carry a range of proposals for modernizing medical product testing and approval. In addition to the agreed-on PDUFA
plan, proposed legislative "enhancements" to the bill aim to make the regulatory process more efficient and predictable. The
Senate Health, Education, Labor, and Pensions Committee approved its Food and Drug Safety and Innovation Act (FDASIA) in
April, but acknowledged that it still needed to resolve several issues related to innovation and supply chain security before
the bill comes up for vote by the full Senate.
Debate continues over incentives for manufacturers to develop new antibiotics and ways to encourage greater FDA use of priority
review and fast-track approval strategies to speed new treatments to market. Sponsors would like more flexibility for scientific
experts with ties to industry to serve on FDA advisory committees. Both manufacturers and patient advocates want to expand
FDA's use of the accelerated approval process, an option that has some agency support.
At the April annual meeting of the Food and Drug Law Institute (FDLI), FDA Commissioner Margaret Hamburg agreed that legislative
language could provide "clarity to industry and the public" on the use of accelerated approval for "a wide variety of diseases
and conditions, including rare diseases." Hamburg also backed proposals to codify the concept of "breakthrough drugs"—products
that elicit such a dramatic response in early clinical trials that they warrant market approval based on limited clinical
Yet, FDA doesn't want overly proscriptive legislation. Hamburg said nothing about appointing an FDA "chief innovation officer"
with authority to ensure that reviewers accept data from unconventional clinical research programs previously okayed by the
agency. FDA also opposes industry's proposal to expand its mission statement from "promoting the public health" to include
"spurring economic growth." Agency officials say it's impossible to calculate how approval or rejection of a new drug or medical
device would affect jobs and growth, as one sponsor might gain from approval, but a competitor could lose.
Hamburg expressed concern that the "anti-government and anti-regulation sentiment" expressed in some legislative measures
could "lower FDA's high public health standards that have served patients, consumers, industry, and the public health for
so long, and so well." High standards for safety and efficacy, she said, "will ensure that innovations actually help patients,"
and that they receive coverage from third-party payers.
FDA highlighted its increased commitment to drug safety over the last five years in a report from the Center for Drug Evaluation
and Research (CDER) on "Advances in FDA's Safety Program for Marketed Drugs." CDER now spends equal resources on post-market
oversight as on pre-market approval, reported Director Janet Woodcock, and new authorities have enabled the agency to require
more than 385 postmarket drug safety studies, to mandate 65 new safety labeling changes, and to initiate 64 risk evaluation
and mitigation strategies since 2008.
However, a report from the Institute of Medicine on "Ethical and Scientific Issues in Studying the Safety of Approved Drugs"
calls for the FDA to do more to monitor and disclose safety issues involving marketed medicines. An expert panel, which launched
this study in 2010 to help FDA prevent future Vioxx-type safety crises, recommended that FDA create a comprehensive, publicly
available document to map drug risks and safety concerns throughout the product lifecycle. CDER officials dismissed that idea,
noting that developing such a Benefit and Risk Assessment and Management Plan, or BRAMP, for every approved drug would be
"challenging" given the agency's limited resources and probably would require lengthy new rule-making.
What FDA would like to see in the PDUFA legislation is enhanced authority to ensure the safety and quality of drugs and active
ingredients now imported from all over the world, as described in its new report on "Global Engagement" and last year's "Pathway
to Global Product Safety and Quality." These documents note FDA's increased overseas presence through its network of international
offices, along with its efforts to strengthen regulatory agencies in other countries, to collaborate on science-based standards,
to share knowledge and inspection resources, and to develop a range of joint surveillance and preparedness activities.
At the FDLI meeting, Hamburg cited a number of legislative provisions that would enable FDA to deal with rising global drug
production: make it easier for FDA to share confidential information with trusted regulatory authorities; enable FDA to refuse
admission and to destroy unsafe drug imports; require manufacturers to report to FDA threats to the supply chain; and require
a "robust" system to track and trace drugs throughout the supply chain.
The proposed generic drug user fee program, she noted, will support more frequent inspections of foreign manufacturers of
active ingredient and drug products. And manufacturers already are reporting earlier to FDA about looming shortage situations.
But industry is wary of legislation that sets stiff penalties for a host of reporting and disclosure requirements. And manufacturers
don't want to invest millions in a system able to track drugs down to the individual bottle or vial level. The debate continues.
Jill Wechsler is Pharmaceutical Executive's Washington correspondent. She can be reached at email@example.com